🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to results published in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This establishes an comparable level with the existing first-line therapy, which involves an injection and a pill. The study enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have voiced positive views. Access to a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.